Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02041533
Title An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Paclitaxel

Cisplatin

Pemetrexed Disodium

Carboplatin

Gemcitabine

Age Groups: adult
Covered Countries USA | CAN

Additional content available in CKB BOOST